Drug intelligence / Profile preview

ME-D3

Development stage
Unknown
Lead developer
Systopic Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

ME-D3 is an oral fixed-dose combination multivitamin and antioxidant supplement developed and marketed by Systopic Laboratories. It is primarily indicated for the management of diabetic neuropathy, peripheral neuropathy, alcoholic neuropathy, and general nutritional deficiencies. The formulation contains five active ingredients: methylcobalamin (an active form of vitamin B12 that supports myelin sheath formation and nerve regeneration), alpha-lipoic acid (a potent antioxidant that reduces oxidative stress and improves microvascular blood flow to nerves), pyridoxine (vitamin B6, essential for neurotransmitter synthesis and amino acid metabolism), folic acid (vitamin B9, which aids in red blood cell production and DNA synthesis), and cholecalciferol (vitamin D3, which regulates calcium homeostasis and supports neuronal health). Together, these components work synergistically to nourish and repair damaged nerve fibers, alleviate neuropathic pain symptoms such as tingling and numbness, and correct underlying vitamin deficiencies.

Brand names
ME D3ME-D3ME-D-3ME-D 3
Other names
Alpha-lipoic acid + folic acid + methylcobalamin + pyridoxine + cholecalciferolAlpha-lipoic acid + folic acid + methylcobalamin + pyridoxine + vitamin D3
02

Targets

DHFR (Dihydrofolate reductase)FOLR1 (FRα)MTR (Methionine synthase)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PDXK (Pyridoxal kinase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on ME-D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME-D3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call